Epitalon Deep-Dive
Also known as: Epithalon · Epithalamin · AEDG · Ala-Glu-Asp-Gly
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on the bovine pineal extract epithalamin. Researchers investigate its proposed effects on telomerase activity, telomere length, and pineal-mediated circadian and endocrine signaling. The original research line traces to the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson and colleagues) over multiple decades.
Plasma Half-Life
Short (estimated minutes; precise pharmacokinetics not well-published)
Logarithmic scale · 30 min mapped
Tissue Residency
Functional duration proposed to extend beyond plasma window via signaling effects
Quick Facts
- Typical dose
- 5–10 mg per session, loaded over 10–20 day blocks
- Range
- 5 mg – 20 mg per session
- Route
- Subcutaneous injection. Some research uses intranasal or oral formulations with reduced bioavailability.
- Cycle pattern
- Common practitioner pattern: 10–20 day loading block, then 3–6 month off-cycle. Some longevity protocols repeat the loading block 2x per year.
- Primary evidence tier
- Experimental
Mechanism of Action
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on the bovine pineal extract epithalamin. Researchers investigate its proposed effects on telomerase activity, telomere length, and pineal-mediated circadian and endocrine signaling. The original research line traces to the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson and colleagues) over multiple decades.
Researchers investigate Epitalon in the broader context of the Longevitycompound class. The compound's proposed relationship to underlying physiology is typically framed against the ATP Shortage axis — a framework DoseCraft uses to organize research priorities across the 90+ compound library.
In the practitioner corpus that trains the DoseCraft AI copilot, Epitalon's mechanism is repeatedly cross-referenced against its pharmacokinetic profile (plasma half-life Short (estimated minutes; precise pharmacokinetics not well-published)) because dosing cadence, stack selection, and cycling structure all derive from the PK window. This is the core difference between a static calculator and a PK-aware reasoning layer.
Pharmacokinetics
Plasma Half-Life (Logarithmic)
Short (estimated minutes; precise pharmacokinetics not well-published)
Logarithmic scale · 30 min mapped
Tissue Residency
Functional duration proposed to extend beyond plasma window via signaling effects
Epitalon has a plasma half-life of approximately Short (estimated minutes; precise pharmacokinetics not well-published). This window is the primary driver of every downstream protocol decision: dosing frequency, stack overlap, cycling length, and the observable duration of subjective response.
Beyond the plasma window, functional duration proposed to extend beyond plasma window via signaling effects. This tissue-residency or functional-duration behavior is why practitioner protocols often deviate from what raw plasma half-life alone would suggest.
In the DoseCraft PK model, this compound is mapped onto the same decay-curve framework that powers the half-life visualizer in the app — every stack built in the Protocol Builder factors in the half-life overlap of Epitalonalongside any co-administered compounds. Static calculators elsewhere ignore this; it's why the practitioner corpus consistently flags half-life literacy as a top-three safety variable.
From real clinicians · not PubMed abstracts
Practitioner Protocols
Practitioner Corpus
Sourced from clinician-validated protocols, bloodwork reviews, and cycle audits. Not PubMed. Not Reddit.
Clinicians focused on longevity research treat Epitalon as the canonical pineal-axis peptide, citing the multi-decade Khavinson research lineage as the primary evidence base. In protocol audits we've reviewed, the loading-block pattern (10–20 days of daily injections, followed by 3–6 months off) is near-universal, distinguishing Epitalon from continuous-use peptides. Practitioners caution that the pharmacokinetic data is sparse compared to mainstream peptides and that the proposed telomerase mechanism remains an active research area without confirmed human telomere-length outcomes outside the original Russian research line.
Dosing
5–10 mg per session, loaded over 10–20 day blocks
Subcutaneous injection. Some research uses intranasal or oral formulations with reduced bioavailability.
Cycle
Common practitioner pattern: 10–20 day loading block, then 3–6 month off-cycle. Some longevity protocols repeat the loading block 2x per year.
Evidence Breakdown
Every finding about Epitalonis categorized across three independent evidence lanes. You always know what research tier you’re acting on.
- Long-running Russian clinical research line (Khavinson and colleagues) reports outcomes across decades. Independent replication outside this research line is limited.
- Practitioner consensus treats Epitalon as the canonical pineal-axis longevity peptide. Loading-block protocol pattern is near-universal.
- Telomerase mechanism remains under active research investigation. Emerging community protocol logs explore stacking with NAD+ and other longevity compounds.
Cycling & Stack Considerations
Cycling Protocol
Common practitioner pattern: 10–20 day loading block, then 3–6 month off-cycle. Some longevity protocols repeat the loading block 2x per year.
Common Stacks
- •Epitalon + NAD+ (longevity loading-block stack)
- •Epitalon + GHK-Cu (longevity research stack)
- •Epitalon solo (the original Khavinson protocol)
Interactions & Overlap
- •NAD+ (often stacked in longevity protocols)
- •Melatonin (mechanistically related via pineal axis; practitioner approaches vary)
- •GHK-Cu (longevity research stack)
Honest negatives · the part other trackers skip
Contraindications & Watch-Outs
Research Watch-Outs
- Active malignancy — telomerase-related mechanisms theoretically contraindicated
- Pregnancy and lactation — no human safety data
- Pineal disorders — practitioner consultation required
Epitalon FAQs
What is the typical Epitalon dose?
The most common practitioner protocol uses 5–10 mg per session, dosed daily across a 10–20 day loading block. The block is then repeated every 3–6 months.
What is the half-life of Epitalon?
Plasma half-life is short — estimated in the minutes range. Precise pharmacokinetics are not well-published. Practitioner protocols rely on the loading-block accumulation pattern rather than sustained plasma exposure.
What is the Khavinson protocol?
The Khavinson protocol refers to the original loading-block pattern developed by the St. Petersburg Institute of Bioregulation and Gerontology — typically 10 mg daily for 10–20 days, repeated 1–2x per year.
Does Epitalon increase telomere length?
Telomerase upregulation is the proposed mechanism, sourced from the original Khavinson research line. Independent confirmation of human telomere-length outcomes outside this research line is limited. The mechanism remains an active research area.
Can Epitalon be taken orally?
Subcutaneous injection is the dominant practitioner route. Intranasal and oral formulations exist but have reduced bioavailability and are less common in research protocols.
How often should Epitalon be cycled?
Common longevity protocols repeat the 10–20 day loading block every 3–6 months. Some practitioners run the block 2x per year as a standardized longevity research approach.
Is Epitalon FDA approved?
Epitalon is not FDA approved for any indication and is sold for research use only. The original research line is published primarily in Russian-language journals.
Related Compounds
Track your Epitalon protocol in DoseCraft
The PK-aware protocol builder models Short (estimated minutes; precise pharmacokinetics not well-published) decay, checks stack overlap, and flags contraindications — built on the same practitioner corpus that powers this page.
See pricingFor research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Content on this page is educational and does not constitute medical advice, dosing guidance, or a protocol recommendation. Consult a qualified clinician before undertaking any research involving peptide compounds.